Last reviewed · How we verify
ACL/FOR
ACL/FOR is a medication that helps to prevent blood clots from forming in the heart.
ACL/FOR is a medication that helps to prevent blood clots from forming in the heart. Used for Prevention of stroke and systemic embolism in non-valvular atrial fibrillation.
At a glance
| Generic name | ACL/FOR |
|---|---|
| Also known as | aclidinium/formoterol, Duaklir |
| Sponsor | Queen's University |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACL/FOR works by inhibiting the coagulation cascade, specifically targeting the factor Xa enzyme. This leads to a reduction in the formation of blood clots, which can cause strokes and other cardiovascular events.
Approved indications
- Prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Common side effects
- Major bleeding
- Gastrointestinal bleeding
- Liver enzyme elevation
Key clinical trials
- The Comparison of Tunnel Morphology and Graft Healing in Anterior Cruciate Ligament Reconstructions Using Peroneus Longus And Hamstring Tendons (NA)
- Preoperative Rehabilitation for Patient With an ACL Injury (NA)
- Safety and Performance Study of the FAST-FIX FLEX System for Meniscal Repairs and Meniscal Transplantations
- New Care Pathway Using Automated Dynamic Laximetry (NA)
- Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes (NA)
- Are Clinical Outcomes Unchanged by ALL Fixation at 0° or 30° of Knee Flexion in Combined ACL-ALL Reconstruction? Despite Numerous Technical Descriptions of Anterolateral Procedures, There is Limited Knowledge Regarding the Effect of Knee Flexion Angle During Graft Fixation. (NA)
- Effectiveness of Blood Flow Restriction in Postoperative Rehabilitation for Anterior Cruciate Ligament Injuries. A Pilot Study. (NA)
- Effect of Internal Brace on Outcomes Following ACL Reconstruction With BTB Autograft (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |